Vidyya Medical News Service
*
Volume 7 Issue 57 Published - 14:00 UTC 08:00 EST 26-Feb-2005 Next Update - 14:00 UTC 08:00 EST 27-Feb-2005
little clear gif used for spacer
 
 

Clinical Trials: Bipolar disorder (manic-depressive illness)

(26 February 2005: VIDYYA MEDICAL NEWS SERVICE) -- FEATURED STUDIES

  • Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
    Treatment study; outpatient. A long-term study of current treatments for bipolar disorder, including medications and psychosocial therapies. Ages 15 and up. Locations across the U.S.
  • Mifepristone and Bipolar Depression.
    Treatment study, inpatient. This 4-week study tests the efficacy of the medication mifepristone (Mifeprex®), compared to placebo, in the depression phase of bipolar I or II disorder. Ages 18-75. NIH Clinical Center, Bethesda, MD.

  • Bipolar Depression and Riluzole.
    Treatment study; inpatient or outpatient. This 8-week study examines the efficacy and safety of the medication riluzole (Rilutek®) for bipolar depression in patients without psychotic features. Ages 18-70. NIH Clinical Center, Bethesda, MD.
  • Treatment of Early Age Mania.
    Treatment study; outpatient. This study will evaluate the effectiveness of the medications lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania. Ages 6-14. Locations across the U.S.
  • Relapse Prevention for Bipolar Type II Disorder.
    Treatment study; outpatient. This 62-week study will compare the safety and effectiveness of fluoxetine (Prozac®), lithium, the combination of these two medications, and placebo in treating and preventing recurrent depressive episodes in people with bipolar type II disorder. Ages 18 and older. Philadelphia, PA.
  • Treatment and Prevention of Early-Onset Bipolar Disorder Symptoms.
    Treatment study; outpatient. This study will compare divalproex (Depakote®) plus olanzapine (Zyprexa®) to lithium plus olanzapine to determine the effectiveness in treating adolescents with bipolar disorder. Ages 12-18. Glen Oaks, NY.
  • Family Intervention for Mental Illness and Substance Abuse.
    Treatment study; outpatient. This study will evaluate a family intervention program for individuals with bipolar disorder, schizophrenia, or schizoaffective disorder and co-occurring substance use disorders. Ages 18-65. Chelsea, MA and Santa Fe Springs, CA.
  • ECT Plus Medication for Treatment of a Depressive Episode.
    Treatment study; outpatient. This study will evaluate the effectiveness of electroconvulsive therapy (ECT) administered with medication for the treatment of a major depressive episode (unipolar or bipolar) and will compare two types of ECT. Ages 18 and older. Locations across the U.S.
  • Felbamate and Bipolar Depression.
    Treatment study, inpatient. This 9-week study will test the efficacy of the medication felbamate (Felbatol®) compared to placebo in the depression phase of bipolar I or II disorder. Ages 18 and older, with a history of nonresponse or poor tolerance to standard treatments. NIH Clinical Center, Bethesda, MD.
  • Clozapine and Bipolar I Mania.
    Treatment study; inpatient. This 4-week study examines the efficacy of the antipsychotic medication clozapine (Clozaril®), compared to placebo, for mania that has not responded to other treatment. Ages 18-60. NIH Clinical Center, Bethesda, MD.
  • Bipolar Depression and Brain Imaging.
    Evaluation study; inpatient and outpatient. This study assesses the function of brain chemicals and hormones in mood disorders (major depression and bipolar depression) using different scanning techniques. Ages 18-60. NIH Clinical Center, Bethesda, MD.
  • Pramipexole and Bipolar II Depression.
    Treatment study; inpatient. This 6-week study will examine the effectiveness of pramipexole (Mirapex®) in the depression phase of bipolar II disorder. This is an inpatient study of medication or placebo that will be added on to current treatment of lithium or valproate. Ages 18-70. NIH Clinical Center, Bethesda, MD.
  • Tamoxifen and Bipolar I Mania.
    Treatment study; inpatient. This 4-week study will test the efficacy of the medication tamoxifen (Nolvadex®), compared to placebo, for patients in the manic phase of bipolar I disorder. Men, ages 18-60. NIH Clinical Center, Bethesda, MD.
  • Genetics & Bipolar Disorder.
    Evaluation study, Outpatient. This study looks to identify genes that may affect a person’s chances of developing bipolar disorder and related conditions. Ages 18 and up. NIH clinical Center, Bethesda, MD.
  • Childhood Bipolar Disorder.
    Evaluation study; inpatient and outpatient. This study evaluates the development and course of childhood bipolar disorder. This is a 4-year study with intensive involvement over the first 6 weeks and follow up visits about every 6 months. One 3-day inpatient stay. Ages 6-17. NIH Clinical Center, Bethesda, MD.

Additional NIH Studies

Search ClinicalTrials.gov for more NIH/NIMH studies on Bipolar Disorder


© Vidyya.
 
 

  More Today in Vidyya